Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has scheduled a Board meeting on Friday, May 23, 2025, to approve its audited standalone and consolidated financial results for the quarter and full year ended March 31, 2025. The Board will also consider and recommend a dividend, if any, on equity shares for FY25. Pursuant to SEBI's insider trading regulations, the trading window for directors and other designated persons is closed from March 31, 2025 to May 25, 2025, covering the pre- and post-results period. The intimation has been filed with both NSE and BSE under Regulation 29 of the Listing Obligations and Disclosure Requirements.
This is a routine pre-earnings filing and does not itself move the stock, but investors should watch the May 23 results announcement closely for actual earnings and any dividend declaration, which could trigger a price reaction.